To the Editor:Transplacental digoxin therapy has been proven effective in converting fetal supraventricular arrhythmia(SVA)to sinus rhythm or achieving ventricular rate control,significantly improving fetal intrauteri...To the Editor:Transplacental digoxin therapy has been proven effective in converting fetal supraventricular arrhythmia(SVA)to sinus rhythm or achieving ventricular rate control,significantly improving fetal intrauterine outcomes.[1–3]However,limited data exist from large patient populations in China.Additionally,concerns remain regarding the relatively high non-response and intrauterine relapse rates during prenatal digoxin treatment.[4,5]Studies exploring the underlying risk factors for digoxin non-response and intrauterine relapse are limited.Therefore,this study aimed to analyze the Chinese data on outcomes and follow-up of fetal SVA treated with prenatal digoxin monotherapy and investigate risk factors associated with unresponsiveness and intrauterine relapse after transplacental digoxin treatment.展开更多
基金This work was supported by grants from the Natural Science Foundation of Sichuan Province(Nos.2024YFFK0272,2024YFFK0078,2024NSFSC1711,2025ZNSFSC1674,and 2025ZNSFSC0705)Key Research and Development Project of Chengdu Science and Technology Bureau(Nos.2024-YF05-00237-SN and 2024-Y05-00506-SN)+1 种基金National Natural Science Foundation of China(No.82370236)National Key Research and Development Program of China(No.2022YFC2703902).
文摘To the Editor:Transplacental digoxin therapy has been proven effective in converting fetal supraventricular arrhythmia(SVA)to sinus rhythm or achieving ventricular rate control,significantly improving fetal intrauterine outcomes.[1–3]However,limited data exist from large patient populations in China.Additionally,concerns remain regarding the relatively high non-response and intrauterine relapse rates during prenatal digoxin treatment.[4,5]Studies exploring the underlying risk factors for digoxin non-response and intrauterine relapse are limited.Therefore,this study aimed to analyze the Chinese data on outcomes and follow-up of fetal SVA treated with prenatal digoxin monotherapy and investigate risk factors associated with unresponsiveness and intrauterine relapse after transplacental digoxin treatment.
